Cyclodextrin-based nanosponges: effective nanocarrier for tamoxifen delivery

Pharm Dev Technol. 2013 May-Jun;18(3):619-25. doi: 10.3109/10837450.2011.649855. Epub 2012 Jan 12.

Abstract

The purpose of the present study was to develop Tamoxifen loaded β-cyclodextrin nanosponges for oral drug delivery. The three types of Tamoxifen loaded β-cyclodextrin nanosponges were synthesized by varying the molar ratios of β-cyclodextrin to carbonyldiimidazole as a crosslinker viz. 1:2, 1:4 and 1:8. The Tamoxifen nanosponge complex (TNC) with particle size of 400-600 nm was obtained by freeze drying method. Differential scanning calorimetry, Fourier transformed infra-red spectroscopy and X-ray powder diffraction studies confirmed the complexation of Tamoxifen with cyclodextrin nanosponge. AUC and Cmax of TNC formulation (1236.4 ± 16.12 µg · mL(-1) h, 421.156 ± 0.91 µg/mL) after gastric intubation were 1.44 fold and 1.38 fold higher than plain drug (856.079 ± 15.18 µg · mL(-1) h, 298.532 ± 1.15 µg/mL). Cytotoxic studies on MCF-7 cells showed that TNC formulation was more cytotoxic than plain Tamoxifen after 24 and 48 h of incubation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Proliferation / drug effects
  • Cyclodextrins / administration & dosage
  • Cyclodextrins / chemistry*
  • Drug Carriers / administration & dosage
  • Drug Carriers / chemistry*
  • Drug Delivery Systems / methods*
  • Humans
  • MCF-7 Cells
  • Nanospheres / administration & dosage
  • Nanospheres / chemistry*
  • Random Allocation
  • Rats
  • Tamoxifen / administration & dosage
  • Tamoxifen / chemistry*
  • X-Ray Diffraction

Substances

  • Cyclodextrins
  • Drug Carriers
  • Tamoxifen